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Edited by Lukas HuberAbstract Two-dimensional electrophoresis and Matrix-assisted
laser desorption ionization-time of ﬂight-time of mass spectrom-
etry were used to detect the diﬀerentially expressed proteins in
serum of tientsin albinao 2 mice with spontaneous breast cancer,
normal tientsin albinao 2 mice and tientsin albinao 1 mice. Only
nuclear clusterin (n-CLU) was expressed in tientsin albinao 1.
Immunohistochemistry and western blot validated that n-CLU
was present in normal tientsin albinao 2 and tientsin albinao 1
mammary epithelium, and secretory clusterin expressed in the
cytoplasm of normal tientsin albinao 2 mammary epithelium
and spontaneous breast cancer. n-CLU may play an important
role in tientsin albinao 2 spontaneous breast cancer initiation
and development.
 2007 Published by Elsevier B.V. on behalf of the Federation of
European Biochemical Societies.
Keywords: Two-dimensional electrophoresis; Electrospray ion
trap mass spectrometry; n-Clusterin; Spontaneous breast
cancer1. Introduction
With breast cancer morbidity increasing worldwide [1],
breast cancer has become a signiﬁcant threat to woman life.
Many studies of breast cancer have focused on the levels of
DNA and mRNA, but the function of a gene is actually ful-
ﬁlled by the expression of its protein [2–4]. Mice are frequently
used in genetic studies, as the genetic background of many par-
ticular strains has been established. After selection of many
years, Tianjin Medical University has established two sponta-
neous breast cancer models: the TA1 strain has a low incidence
of spontaneous breast cancer, while the TA2 strain has a high
incidence [5]. Studies have indicated that skin transplantation
is successful between F1 hybrids of TA1 and TA2, demonstrat-Abbreviations: CLU, clusterin; s-CLU, secretory clusterin; n-CLU,
nuclear clusterin; NLSs, nuclear localization signals; MALDI-TOF-
MS, Matrix-assisted laser desorption ionization-time of ﬂight-time of
mass spectrometry
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TA2 mice have a high incidence of spontaneous breast cancer
without any chemical stimulus [6,7].
TA1 and TA2 mice have similar genetic backgrounds. In this
study, the serum total protein extracts from TA1 mice, TA2
mice and TA2 mice that had spontaneous breast cancer were
analyzed by two-dimensional polyacrylamide gel electrophore-
sis (2D-PAGE) with immobilized pH gradients followed by
mass spectrometry to detect proteins that are absent or
expressed in the serum of normal TA1 mice [8]. Immunohisto-
chemical staining and Western blot were performed to validate
the expression of proteins.2. Materials and methods
2.1. Mice
There were four TA2 mice that had spontaneous breast cancer. Two
of these mice have bred three times, and the others have bred four
times. The average time it takes for is about 278 days. Four normal fe-
male TA1 mice coming from the same mother were selected, and so as
the 4 normal female TA2 mice. The age of these particular TA1 and
TA2 mice was almost the same, about 7–8 weeks.2.2. Two-dimensional electrophoresis and mass spectrometric detection
Blood was collected from the epicanthic venous plexus of the mice
and the serum was separated from the other blood components.
Two-dimensional electrophoresis with immobilized pH gradients was
performed according to the methods of Gorg et al. [9] and the Manual
of Operations for the IPGphor isoelectric focusing system. The serum
sample (15 ll) was loaded into the sample cup, ensuring that the IPG
strip was covered with 2–3 ml of mineral oil. Isoelectric focusing was
conducted with the immobilized pH 3–10 non-linear gradient strips
(Amersham Biosciences) at 0–500 V for an hour, 500 V for 5 h, 500–
3500 V for 5 h and 3500 V for 12 h. After IEF two SDS–PAGE gels
(12%) were made to perform the second dimension. Electrophoresis
was stopped when the dye front was approximately 1 mm from the
bottom of the gel. After electrophoresis, the gel was removed from
the gel cassette and stained [10].2.3. Analysis of the gel image
ImageMaster 2D 5.0, Imagescanner and LabScan image collection
software were used to capture, store, evaluate, and present information
contained in the gel. All of the data were analyzed in SPSS10.0 and Ex-
cel. The spots absent in one sample and the spots which quantity in-
crease or decrease three-fold were deﬁned as the diﬀerential proteins.
2.4. Mass spectrometric detection
The diﬀerentially expressed protein spots were excised and de-
stained. Enough digestion buﬀer was added to just cover the gel slices
and make them swell, and then the digestion buﬀer was removed andation of European Biochemical Societies.
3278 B. Sun et al. / FEBS Letters 581 (2007) 3277–3282replaced with 20 ll of 50 mM NH4HCO3. The digestion proceeded
overnight at 37 C. The peptides were extracted twice with 35 ll
0.1% triﬂuoroacetic acid (TFA) and 50% acetonitrile (ACN). All of
the extracts were pooled and dried with nitrogen. The dry extracts were
then re-dissolved in 3 ll of 0.1% TFA and 50% ACN. 0.3 ll samples
and 0.3 ll CHCA solution were mined and spot on the plate. The mass
spectrometer was operated under 18 kV accelerating voltage in the
reﬂectron mode and a m/z range of 800–4000. Peak lists (S/N > 10)
obtained from MALDI-TOF-MS were extracted from the raw data
and were analyzed by DPS ExplorerTM software (Version 3.5,
Applied Biosystems, USA). They were interpreted with MASCOT
(Version 1.9.01, Matrix Science, Boston, MA, USA) and the proteins
with over 95% CI were identiﬁed. The tandem mass spectra from the
MS/MS experiments were searched against the non-redundant protein
sequence database downloaded from NCBI (www.ncbi.nlm.nil.
gov060915). Searches against the NCBI database revealed individual
ion scores above 33 for 95% peptide identity signiﬁcance level, and
above 40 for the 95% level. The minimum criteria for protein identiﬁ-
cation were set to two unique peptides above the 99% level. If the pro-
tein was identiﬁed twice only the best peptide coverage was reported.3. Immunohistochemistry
The normal mammary gland tissue and the breast cancer tis-
sue of the above 12 mice were ﬁxed with formalin and then
processed and embedded in paraﬃn. Five micrometer-thick
paraﬃn-embedded tissue sections were cut and stained immu-
nohistochemically (SP method). The primary antibody (mouse
monoclonal antihuman Clusterin-a/b, clone: H-330:sc-8354,
Santa Cruz Biotechnology) was diluted to 1:200. The sections
were pretreated with citrate buﬀer (0.01 M citric acid, pH 6.0)
for 20 min at 100 C in a microwave oven. The slides were
incubated overnight at 4 C, washed with PBS, and incubated
with the biotinylated secondary antibody and preformed avi-
din-biotinylated peroxidase complex by turns. The color was
developed with DAB. Finally, all of the sections were counter-
stained with hematoxylin.4. Western blot
The normal breast tissue and breast cancer tissue were ly-
sated with the buﬀer (1% SDS, 10 Mm Tris–Hcl, pH 7.6,
20 lg/ml aptotenin, 20 lg/ml leupeptin and 1 mM AEBSF).
The protein concentrations were determined using Bradford
method. Five micrograms of protein were separated on 12%
of SDS–PAGE gels and transferred to PVDF membranes.
After blocked with 10% non-fat milk, the membranes wereFig. 1. A TA2 mouse with spontaneous breast cancer. (A) The tumor is in the
section shows the tumor cells formed many nests or tubules.incubated with anti-clusterin polyclonal antibody (Clusterin-
a/b, clone: H-330:sc-8354, Santa Cruz Biotechnology Inc.,
1:200 dilution) at 4 C overnight. After washing for three
times, the membranes were incubated with goat anti-rabbit
IgG at room temperature for 30 min. The signals were devel-
oped with the ECL kit (Beijing Zhongshan Biotechnology
Inc.) and using anti b-actin antibody (sc-1616, Santa Cruz Bio-
technology Inc.) as an internal control.5. Results
5.1. Pathological examination
The location of each spontaneous tumor in the mice is diﬀer-
ent: two of the four were located in the mammary gland near
the forward limb, while the other two were located in the
fourth mammary gland near the hind limb. Under the light
microscope, the tumor cells formed many nests or tubules
(Fig. 1A and B). The spontaneous breast cancer cells were neg-
ative for ER, PR, and Her-2.
5.2. Analysis of the 2D electrophoresis maps
Serum protein from mice with spontaneous breast cancer,
normal TA1 mice and TA2 mice was separated by IPG-
2DE-SDS–PAGE, with every sample tested three times.
According to analysis by ImageMaster 2D 5.0, every sample
had good reproducibility. The gel was silver-stained after 2D
electrophoresis, and 2DE maps with good resolution and
reproducibility were obtained. Silver staining was preferred
over Coomassie blue staining because the resolution is higher
with silver staining. Isoelectric focusing, SDS–PAGE and
staining were performed identically for these six maps. The
molecular mass of the proteins ranged between 10 and
100 kD, the isoelectric point was between 4 and 9, and the
number of acidic points exceeded the number of basic points.
Comparing the six maps, the main diﬀerentially expressed pro-
teins were located between PI 4.5 and 6.5. Sorting of the pro-
tein spots from the three groups can be seen in Table 1.5.3. Analysis of the diﬀerentially expressed proteins in mice with
spontaneous breast cancer, normal TA1 and TA2 mice
Analysis with ImageMaster 2D 5.0 software indicated that
the main diﬀerentially expressed proteins were located in the
range between PI 4.5 and 6.5 and had a molecular mass
between 25 and 97 kD. A diﬀerence more than 10 times wassecond mammary gland of the forward limb. (B) H&E stain of a tumor
Table 1
Number of protein points matched across 2D gels for each mouse type
TA1 TA2 TA2 with spontaneous breast cancer
TA1 305 (100%) 271 (88.85%) 298 (97.7%)
TA2 271 (81.14%) 334 (100%) 303 (90.72%)
TA2 with spontaneous breast cancer 295 (84.53%) 303 (86.82%) 349 (100%)
Table 2
Proteins expressed diﬀerentially among the three groups of mice
ID TA2 mice with spontaneous breast cancer Normal TA2 mice Normal TA1 mice Identiﬁed by mass spectrometry
0204 Expressed Downregulated Absent Haptoglobin
0205 Expressed Downregulated Absent ATP-binding protein
2208 Expressed Downregulated Absent Hypothetical protein MtrDRAFT_AC140721g10v1
6614 Expressed Downregulated Absent Modiﬁcation methylase HemK
2627 Downregulated Downregulated Expressed Clusterin precursor
2207 Expressed Downregulated Absent Paraoxonase
6610 Expressed Downregulated Downregulated Pregnancy zone protein
1101 Expressed Downregulated Absent Putative Transaldolase
1201 Expressed Downregulated Absent AGL175Wp
4101 Downregulated Expressed Downregulated SAP
5202 Expressed Downregulated Absent Peptide transporter-like protein
Fig. 3. Number: 2627 serum electrophoresis maps of (A) normal TA1 mice, (B) normal TA2 mice, and (C) TA2 mice with spontaneous breast cancer.
Fig. 2. 2D electrophoresis maps of serum protein from (A) normal TA2 mice, (B) normal TA1 mice, and (C) TA2 mice with spontaneous breast
cancer.
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entially expressed. Diﬀerential protein points were searched
and compared in the three groups (Fig. 2). Eleven diﬀerential
protein points were found, and the expression of these 11 pro-
teins can be seen in Table 2.5.4. Mass spectrographic analysis of the diﬀerentially expressed
proteins and database searches
The diﬀerentially expressed proteins were identiﬁed by mass
spectrometry on the basis of their peptide mass ﬁngerprints
(PMF) (Fig. 3A–C, Table 3). One diﬀerentially expressed
Table 3
Diﬀerential proteins expressed among the three groups of mice
Accession
number
Protein name MW (Da) Protein PI Sequence
coverage (%)
Ion score Ion score
C.I.%
gij8248739 Haptoglobin 38749.51172 6.08 56 88.86000061 99.9997123
gij95108443 ATP-binding protein 70630.64844 5.59 47 50.40000153 97.32645933
gij92870298 Hypothetical protein MtrDRAFT_AC140721g10v1 18858.36914 8.52 76 41.479999542 99.68657546
gij77965817 Modiﬁcation methylase HemK 29695.49023 4.86 55 53.98999977 98.5432135
gij729152 Clusterin precursor 51655.71000 5.46 46 86.5552847 98.541879
gij1628624 Paraoxonase 39540.32031 5.07 49 74.31999969 99.99137276
gij34785996 Pregnancy zone protein 165775.8125 6.24 66 47.95999908 99.567824
gij52005360 Putative Transaldolase 24397.60938 6.75 77 54.00999832 97.07588288
gij44985692 AGL175Wp 43013.06641 5.62 59 46.49000168 95.0347847
gij297547 SAP 26230.26953 5.98 68 101.7900009 100
gij34393815 Peptide transporter-like protein 33643.53906 10.99 54 66.06999969 96.5428713
Fig. 5. n-CLU expression (A) n-CLU is highly expressed in the normal mammary gland of TA1 mice. Positive grains can be seen in breast ductal
epithelial cell nuclei. (B) In TA2 mice positive grains are located in both the cytoplasm and nucleus of breast ductal epithelial cells. (C) TA2
spontaneous breast cancer tissue is n-CLU negative.
Fig. 4. Mass spectrometry on the basis of the peptide mass ﬁngerprints validates that the molecular mass of protein No. 2627 is 51655.71 D and the
protein was found to be n-CLU by searching the public database.
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Its molecular mass is 51655.71 (ID number: 2627.3033), and
the protein was identiﬁed as the clusterin precursor (n-CLU)
by searching the database (Fig. 4). Most of the other diﬀeren-
tially expressed proteins are highly abundant serum proteins,
and have no relation to tumorigenesis.5.5. Immunohistochemical staining and Western blot results
Clusterin-a/b (clone: H-330) can detect the secretory clus-
terin (s-CLU) and n-CLU. As seen in the immunohistochemi-
cal staining, positive grains can be seen in the nucleus of breast
ductal epithelial cells, which implied n-CLU is expressed in the
normal mammary gland of TA1 mice. In TA2 mice positive
Fig. 6. The results of western blot also indicates that clusterin in
mammary epithelium of TA1 mice is 55 kDa isoform, both of 40 kDa
and 55 kDa isoforms are detected in TA2 mice mammary gland and
40 kDa clusterin isoform is present in TA2 spontaneous breast cancer.
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were no positive grains in the nucleolus of the tumor cells.
However, the cytoplasm of tumor cells showed strongly
expression for clusterin (Fig. 5A–C). Western blot analyzed
clusterin proteins expressed in TA1 and TA2 normal breast tis-
sue and TA2 spontaneous breast cancer. The results indicated
that clusterin in mammary epithelium of TA1 mice was 55 kDa
isoform , both of 40 kDa and 55 kDa isoforms were detected in
TA2 mice mammary gland and the expression of 40 kDa clus-
terin isoform was present in TA2 spontaneous breast cancer
(Fig. 6).6. Discussion
The mouse model is the best subject for many genetic stud-
ies, as its genetic background is well known. The TA1 and TA2
mouse strains have a low and a high morbidity of breast can-
cer, respectively [5]. After being inbred for 160 consecutive
generations, TA1 and TA2 mice have highly consistent geno-
types, and they can reproduce healthy oﬀspring.
The morbidity of spontaneous breast cancer in parous fe-
male mice is 84.1% within an average of 280 days after birth,
and the morbidity of virginal mice is 41.4% within an average
of 400 days after birth. The morbidity in TA1 mice is only 1%
[6]. The diﬀerence in morbidity between TA1 and TA2 mice
may be because there are some mutations in the chromosomal
structure of the TA2 strain. The mutations of genes may be re-
sult in diﬀerent proteins expression.
In this study, we used two-dimensional electrophoresis and
mass spectrometry to analyze the serum of mice with sponta-
neous breast cancer, normal TA1 mice and TA2 mice. Using
TA1 mice as the control, we screened serum protein samples
for proteins that are expressed or absent in the TA2 strain. De-
creased expression of clusterin precursor protein can be seen in
mice with spontaneous breast cancer and in normal TA2 mice,
while it is expressed in the TA1 strain. Immunohistochemistry
also indicated n-CLU, located in the nucleus, was expressed in
TA1 mice.
Clusterin, also known as apolipoprotein J (APOJ), testoster-
one-repressed prostate message 2 (TRPM2), sulfated glycopro-
tein 2 (SGP2), complement-associated protein SP-40, and
complement lysis inhibitor (CLI), is a secreted heterodimeric
disulﬁde-linked glycoprotein with a molecular mass of approx-
imately 70 kD [11]. Clusterin maps to 8q21 and encodes a pro-
tein composed of 448 amino acids. Clusterin, ﬁrst isolatedfrom testicular tissue in 1983, is a prostaglandin synthetase
inhibitor. It is expressed in virtually all tissues and is found
in all human body ﬂuids [12]. Clusterin is involved in numer-
ous physiological processes important for carcinogenesis and
tumor growth [13,14], including apoptotic cell death [6,15], cell
cycle regulation, DNA repair [16], cell adhesion, tissue remod-
eling, lipid transport, membrane recycling, and immune system
regulation [17]. Clusterin can also act as a molecular chaperone
to eliminate the metaproteins produced when cells are under
stress [18].
There are two known clusterin protein isoforms generated in
human cells: the secreted form (s-CLU) and the nuclear form
(n-clusterin) [19]. s-CLU expression is initiated by translation
from the ﬁrst AUG codon of the full-length clusterin mRNA.
This precursor protein, with a molecular mass of about 60 kD,
is directed to the endoplasmic reticulum and then it is trans-
ported toward the Golgi apparatus where it is heavily glycos-
ylated and the a and b subunits that are linked by disulﬁde
bonds are cleaved. Under physiological conditions, the mature
70 kD protein that is secreted appears as a smear at 37–40 kD
on a reducing SDS–PAGE immunoblot. Nuclear clusterin (n-
CLU), with a molecular weight of about 55 kD, is synthesized
from a second in-frame AUG codon using an alternatively
spliced n-CLU mRNA. Unlike s-CLU, n-CLU does not un-
dergo subunit cleavage, nor does this protein appear to be
extensively glycosylated. Expression of n-CLU results in a
pro-death signal that inhibits cell growth and survival, so it
is also called a cell death protein [20]. Expression of n-CLU
is induced by cytotoxic stress and it can lead to cell death
[21]. n-CLU’s C-terminal coiled-coil domain can associate with
the DNA double stranded break repair protein Ku70. This do-
main of n-CLU is the minimal region required for Ku70 bind-
ing and apoptosis. The binding of n-CLU and Ku70 can lead
to the formation of Ku70/Ku80 dimers that can aﬀect DNA
non-homologous repair and eventually lead to genomic insta-
bility and cell death. In normal cells, the inactive of nuclear
clusterin precursor (pnCLU) exists in the cytoplasm of normal
cells and has two targets of nuclear localization signals (NLSs).
Under damage, pnCLU can be decorated and form the 55 kDa
nCLU. With the help of NLSs, nCLU transferred into the nu-
cleus and induce the cell apoptosis [21].
It is indicated that clusterin is highly associated with cell
apoptosis and survival [15,22]. The relationship between
clusterin and the pathogenesis and progression of cancer is
determined by the presence of the diﬀerent isoforms, the intra-
cellular location of the protein and the glycosylational modiﬁ-
cations [23–26]. It is reported that clusterin takes part in the
pathogenesis and progression of cancer only after glycosyla-
tion and cellular relocalization [27–29]. The immature precur-
sor and n-CLU exist together in the nucleus of tumor cells,
while the mature clusterin localizes in the cytoplasm. Unlike
glycosylated mature clusterin which can promote the patho-
genesis and progression of cancer [30], n-CLU may be proa-
poptotic [31,32] and is capable of eliminating abnormally
replicating cells to avert tumor progression [33,34].
The antibody we used in this study to detect clusterin a/b is a
polyclonal antibody. It can detect both cytoplasmic clusterin
and n-CLU and can therefore distinguish the glycosylated
mature clusterin from n-CLU depending on the location of
the positive grains. Results from our study show that clus-
terin in breast epithelial cells in TA1 mice is located in the cell
nucleus, suggesting that n-CLU is present in the breast epithe-
3282 B. Sun et al. / FEBS Letters 581 (2007) 3277–3282lial cell nuclei where it plays a part in inhibition of malignant
transformation.
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